NGPOD launched in France
September 20, 2021
NGPOD has launched in France thanks to our new partnership with Gamida
NGPOD Global Ltd, a life science company based in Runcorn, Cheshire, is set to further enter the European market following the announcement of their partnership with Gamida in France. Under the agreement terms, Gamida will be the exclusive distributor for France and French overseas territories for the NGPOD nasogastric tube placement confirmation system.
Gamida is a well-established manufacturer and distributor of medical devices and systems in France and has a strong portfolio of anaesthesiology and surgical products, giving them access to key clinical customers who can use NGPOD. Ms Carole Dautremant, the CEO of Gamida, commented on the agreement, "Over the last three years, all of us at Gamida have followed with great interest the NGPOD device's growth in market share. We are therefore very happy that you have selected us to be your distributor in France. Giving us the opportunity to offer such an innovative product to our customers puts us at the forefront of the revolution in the enteral feeding market of which your company is such an important part."
John Carrington, NGPOD Global CEO, said, "In a large market like France with a complex healthcare system, it was vital that we identified a partner who understands the importance of NGPOD to patient safety and recovery. Gamida has been very impressive in the way they have approached establishing the potential for NGPOD in France, and we are delighted to have this agreement in place."
Marcus Ineson, Chief Marketing Officer NGPOD Global, recognised the support from the Department of International Trade, particularly Gill Barlow and Julie Lebouleux-Linosi, in identifying potential partners in France and navigating the new post-Brexit trade arrangements.
NGPOD is a patented device that, in a UK based clinical trial, has been shown to reduce the risks associated with established methods of nasogastric tube placement, which can lead to serious clinical incidents (Never Events) which cause injury and death to patients. NGPOD also reduces the need for time-consuming, costly x-rays and allows patients to receive nutrition, hydration and medicines without delay supporting their recovery.
NGPOD Ltd manufactures the NGPOD system in the UK and has so far, in 2021, created six new high-quality life science manufacturing jobs at their new facility in Runcorn. Further announcements of other international distribution partnerships are imminent.
More from the blog
July 12, 2022NGPOD enter the south-east Asia Med Tech Market
July 5, 2022NGPOD expand its distribution network into Qatar
April 28, 2022New Customer Experience Representative Joins NGPod Team
WHAT IS NGPOD?
NGPod: Stop "Never Events", improve patient recovery and reduce costs
The NGPod handheld devices overcomes many of the risks associated with existing Nasogastric placement confirmation methods.
- No aspiration required
- No interpretation required. Get a clear "Yes/No" answer
- Rapid result [c.15 seconds]
- Reduce delays to patients treatment, hydration and nutrition
- More cost-effective than testing with pH strips